

August

2023 Release Notes



Ad Hoc

All Pages

Payment Status = Paid has been applied as a default filter to these report pages to help clients avoid overreporting claims unless they specifically want to include unpaid claims.

Population Health

Overuse and Appropriateness

[F23583, F23582, F23587] – This new HEDIS report shows the three new measures from the Overuse and Appropriateness sub-domain.

- (AAB) Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis
- (DDE) Potentially Harmful Drug-Disease Interactions in Older Adults
- (NCS) Non-Recommended Cervical Cancer Screening in Adolescent Females

Overuse and Appropriateness						Measure Name, Measure Rate				Measurement Year		Group Name, Division Name		
						All			2023			All		
Group Name	Members	Eligible Population	Compliant	Non-Compliant	Score	Member Name	Avoidance of Antibiotic Treatment for Acute Bronchitis	Avoidance of Non-Recommended Cervical Cancer Screening	No Potentially Harmful Medication with Dementia	No Potentially Harmful Medication with Falls				
MA001 - Ipsum Non Associates	13,515	483	483		100.0%	ABBOT GARDNER	✓							
Avoidance of Non-Recommended Cervical Can...	13,515	312	312		100.0%	ABDUL HOLDEN		✓						
Avoidance of Antibiotic Treatment for Acute Br...	13,515	171	171		100.0%	ABEL ACEVEDO		✓						
GRHS - Magna Praesent Inc.	3,549	111	96	16	85.0%	ABRAHAM HUMPHREY		✓						
Avoidance of Non-Recommended Cervical Can...	3,549	72	72		100.0%	ABRAHAM STRONG		✓						
Avoidance of Antibiotic Treatment for Acute Br...	3,549	36	23	14	60.5%	ABRAHAM STRONG		✓						
No Potentially Harmful Medication with Falls	3,549	2	1	1	50.0%	ABRAHAM STRONG		✓						
No Potentially Harmful Medication with Deme...	3,549	1		1	0.0%	ABRAHAM STRONG		✓						
MA005 - Gravida Mauris UT LLP	2,328	89	89		100.0%	ABRAHAM STRONG		✓						
Avoidance of Non-Recommended Cervical Can...	2,328	58	58		100.0%	ABRAHAM STRONG		✓						
Avoidance of Antibiotic Treatment for Acute Br...	2,328	31	31		100.0%	ABRAHAM STRONG		✓						
POTTCNTY - Ante Ipsum Limited	1,475	73	73		100.0%	ACTON STAFFORD		✓						
Avoidance of Non-Recommended Cervical Can...	1,475	73	73		100.0%	ACTON STAFFORD	✓							
MA003 - Facilis PC	1,849	67	67		100.0%	ADRIA ONEAL		✓						
Avoidance of Non-Recommended Cervical Can...	1,849	45	45		100.0%	ADRIA ONEAL		✓						
Avoidance of Antibiotic Treatment for Acute Br...	1,849	23	23		100.0%	ADRIA ONEAL	✓							
SARPY - Eget Laoreet Industries	1,417	60	60		100.0%	ADRIA PETERS	✓							
Avoidance of Non-Recommended Cervical Can...	1,417	42	42		100.0%	ADRIA PETERS		✓						
Avoidance of Antibiotic Treatment for Acute Br...	1,417	18	18		100.0%	ADRIA PETERS		✓						
CITYCLUFF - Ultricies Adipiscing Enim C...	1,553	56	56		100.0%	ADRIA PETERS		✓						
Avoidance of Non-Recommended Cervical Can...	1,553	56	56		100.0%	ADRIA PETERS		✓						
MA004 - Magna Praesent Interdum LLC	1,217	52	52		100.0%	ADRIAN HOOD		✓						
Avoidance of Non-Recommended Cervical Can...	1,217	36	36		100.0%	ADRIENNE BLACKWELL		✓						
Avoidance of Antibiotic Treatment for Acute Br...	1,217	16	16		100.0%	ADRIENNE BLACKWELL		✓						
MA014 - Ac Turpis Egestas Corporation	1,282	50	50		100.0%	AHMED BECK		✓						
Avoidance of Non-Recommended Cervical Can...	1,282	31	31		100.0%	AHMED BECK		✓						
Avoidance of Antibiotic Treatment for Acute Br...	1,282	19	19		100.0%	AIKO MONTOYA		✓						
MA011 - Sed Incorporated	1,264	39	39		100.0%	AIKO MONTOYA		✓						
Avoidance of Non-Recommended Cervical Can...	1,264	28	28		100.0%	AIKO MONTOYA		✓						
Avoidance of Antibiotic Treatment for Acute Br...	1,264	11	11		100.0%	AILEEN PITTS		✓						
CTYBELLEVUE - Duis A Institute	795	36	36		100.0%	AILEEN PITTS	✓							

HEDIS Measure Descriptions

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)

Description - The percentage of episodes for members ages 3 months and older with a diagnosis of acute bronchitis/ bronchiolitis that did not result in an antibiotic dispensing event.

Eligible Population

Ages - Members who were 3 months or older as of the Episode Date.

Episode Date - The date of service for any outpatient, telephone, observation or ED visit, e-visit or virtual check-in during the Intake Period with a diagnosis of acute bronchitis/ bronchiolitis.

Episode Date - A 12-month window that begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year. The Intake Period captures eligible episodes of treatment.

Continuous Enrollment - 30 days prior to the Episode Date through 3 days after the Episode Date (34 total days).

Allowable Gap - None

Anchor Date - None

Benefit – Medical and Pharmacy

Event/diagnosis - Identify all members who had an outpatient visit, a telephone visit, an e-visit or virtual check-in, an observation visit, or an ED visit during the Intake Period, with a diagnosis of acute bronchitis/bronchiolitis (Acute Bronchitis Value Set).

Exclusions

- Members in hospice or using hospice services anytime during the measurement year.

Score

Denominator - The eligible population

Numerator – NOT Dispensed prescription for an antibiotic medication (AAB Antibiotic Medications List) on or three days after the Episode Date.

Calculation - The measure is reported as an inverted rate $[1 - (\text{numerator} / \text{eligible population})]$. A higher rate indicates appropriate acute bronchitis/bronchiolitis treatment (i.e., the proportion for episodes that did not result in an antibiotic dispensing event).

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE) *inverted

Description: The percentage of Medicare members 65 years of age and older who have evidence of an underlying disease, condition or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis.

Report each of the three rates separately and as a total rate.

- A history of falls and a prescription for antiepileptics, antipsychotics, benzodiazepines, nonbenzodiazepine hypnotics or antidepressants (SSRIs, tricyclic antidepressants and SNRIs).
- Dementia and a prescription for antipsychotics, benzodiazepines, nonbenzodiazepine hypnotics, tricyclic antidepressants, or anticholinergic agents.
- Chronic kidney disease and prescription for Cox-2 selective NSAIDs or nonaspirin NSAIDs.
- Total rate (the sum of the three numerators divided by the sum of the three denominators).

Eligible Population

Ages - 67 years and older as of December 31 of the measurement year.

Continuous Enrollment - The measurement year and the year prior to the measurement year.

Allowable Gap - No more than one gap in enrollment of up to 45 days during each year of continuous enrollment.

Anchor Date - December 31 of the measurement year.

Benefit – Medical and Pharmacy

Event/diagnosis - Members with at least one disease, condition or procedure in the measurement year or the year prior to the measurement year. Refer to Additional Eligible Population Criteria for each rate.

Exclusions

- Members receiving palliative care.
- Members in Hospice

Rates

- Rate 1: Drug-Disease Interactions—History of Falls and Antiepileptics, Antipsychotics, Benzodiazepines, Nonbenzodiazepine Hypnotics or Antidepressants
- Rate 2: Drug-Disease Interactions—Dementia and Antipsychotics, Benzodiazepines, Nonbenzodiazepine Hypnotics, Tricyclic Antidepressants or Anticholinergic Agents
- Rate 3: Drug-Disease Interactions—Chronic Kidney Disease and Cox-2 Selective NSAIDs or Nonaspirin NSAIDs

Calculation – These rates are shown as an inverse where NOT having a potentially harmful drug is marked as compliance, so a higher rate is better.

Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)

*inverted

Description: The percentage of adolescent females 16–20 years of age who were NOT screened unnecessarily for cervical cancer.

Note: This rate is inverted from the HEDIS definition. This is done to standardize rates across the domain so a higher rate is always better

Eligible Population

Ages - Adolescent females 16–20 years as of December 31 of the measurement year.

Continuous Enrollment - The measurement year.

Allowable Gap - No more than one gap in enrollment of up to 45 days during the measurement year.

Anchor Date - December 31 of the measurement year.

Benefit - Medical

Event/diagnosis - An acute inpatient discharge from July 1 of the year prior to the measurement year through June 30 of the measurement year with any diagnosis of AMI

Exclusions

- Members in hospice

Score

Denominator - The eligible population

Numerator - NO Cervical cytology or HPV test performed during the measurement year. Not having the unnecessary test means the member is compliant.

Model Changes

New Columns

- **vCLAIM[Claim From Batch]** This is a Y/N flag that indicates if the claim is from an active batch or is a processed claim. Only clients that indicate Claims in Batch should be sent to Gateway and Analytics will have data from Claim in Batch. This setting can be changed in VBA Software > System Services > Interface Management. By default, this setting is OFF.
- **vMEMEBER[Gateway Registration Date]** This field is populated with the members VBAGateway registration date.